PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.27%
Revenue growth of 8.27% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
11.47%
Gross profit growth of 11.47% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
16.10%
EBIT growth of 16.10% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
15.53%
Operating income growth of 15.53% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
12.54%
Net income growth of 12.54% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
12.53%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.82%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
12.53%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 3.49%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.38%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 3.41%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
81.38%
5Y CAGR of 81.38% while Medical - Pharmaceuticals is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
63.60%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 1.17%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-100.00%
Negative 3Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
95.12%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 56.92% over a decade. Joel Greenblatt might see a standout compounder of earnings.
95.12%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 22.29%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
58.16%
3Y net income/share CAGR of 58.16% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
124.82%
Equity/share CAGR of 124.82% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
124.82%
5Y equity/share CAGR of 124.82% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
84.15%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.56%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-50.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-50.00%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
30.43%
3Y dividend/share CAGR of 30.43% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
22462.50%
AR growth of 22462.50% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
4.04%
Inventory growth of 4.04% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
13.63%
Asset growth of 13.63% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.35%
BV/share growth of 5.35% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
141.03%
Debt growth of 141.03% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.